Client stories

Optimising Evidence Generation for European Medical Affairs

Life Sciences, LS Medical Affairs

Assessment of the current ‘as-is’ Evidence Generation (EvGen) challenges in Europe, identification of opportunities for improvement, creation of a high-level implementation roadmap and initiation of the delivery of recommendations, including defining the future Operating Model for the EvGen team in Europe. 

What was the challenge?

Delivering impactful evidence is foundational to being successful in the market, and being able to show the true relative medical value of a product when compared to others is critical in maximising patient outcomes.

The current approach to Evidence Generation (EvGen) within the Medical Affairs (MA) European region did not sufficiently meet the needs of Local Operating Countries (LOCs), nor was it consistently applied. There was a disconnect in the necessary understanding of the local market needs in the region and central strategy teams, along with misaligned timelines and processes to effectively develop robust and synergised EvGen plans and then execute them. The region lacked the operational and SME resources to implement the endorsed improvement recommendations that would move the European MA Region towards its EvGen vision.

How did we help?

Moorhouse undertook a two-phased approach to understand the current-state processes and pain points, and to propose and begin implementation of proposed improvement recommendations:

  1. In phase one, we carried out a situational analysis to map the holistic end-to-end EvGen framework, including the key challenges, and collated and analysed survey data to validate initial findings and summarise opportunities. The team then facilitated a two-day workshop driving solution ideation, and recommended improvements, phased to prioritise the most impactful, and balanced with current resource availability.
  2. In phase two, we provided resources to mobilise the Programme Management, standing up six improvement initiatives, and driving the initiation and delivery of recommendations to aid in achieving the client’s vision.

 

Pan-European outcomes of our work include:

  • Higher quality evidence plans, delivering the right evidence, at the right time.
  • A greater number of studies receiving global endorsement and associated budget.
  • Increased transparency of study landscape, enabling the Global Bio-pharma company to pivot quicker to improve the impact and value of the evidence being generated.

What was the impact?

These outcomes culminate in the ultimate benefit of more impactful and strategically aligned evidence being generated, to ensure gaps are closed to help patients and people, to better understand how a treatment will meet their specific needs, leading to optimised outcomes. 

We’re always here to help

Leo Koshutova

Partner, Lead
Life Sciences

Email me